Silence Research Development from 2010 to 2026
| SLN Stock | USD 5.44 0.02 0.37% |
Research Development | First Reported 2012-09-30 | Previous Quarter 17.6 M | Current Value 20.5 M | Quarterly Volatility 5.5 M |
Check Silence Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Silence Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 716 K, Interest Expense of 29.1 K or Other Operating Expenses of 128.7 M, as well as many indicators such as Price To Sales Ratio of 2.1, Dividend Yield of 0.0 or PTB Ratio of 0.68. Silence financial statements analysis is a perfect complement when working with Silence Therapeutics Valuation or Volatility modules.
Silence | Research Development | Build AI portfolio with Silence Stock |
Evaluating Silence Therapeutics's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Silence Therapeutics PLC's fundamental strength.
Latest Silence Therapeutics' Research Development Growth Pattern
Below is the plot of the Research Development of Silence Therapeutics PLC over the last few years. It is Silence Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Silence Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Silence Research Development Regression Statistics
| Arithmetic Mean | 25,610,187 | |
| Geometric Mean | 13,422,506 | |
| Coefficient Of Variation | 107.19 | |
| Mean Deviation | 22,658,359 | |
| Median | 9,743,000 | |
| Standard Deviation | 27,451,546 | |
| Sample Variance | 753.6T | |
| Range | 81.2M | |
| R-Value | 0.90 | |
| Mean Square Error | 157.2T | |
| R-Squared | 0.80 | |
| Slope | 4,875,708 | |
| Total Sum of Squares | 12057.4T |
Silence Research Development History
About Silence Therapeutics Financial Statements
Silence Therapeutics investors utilize fundamental indicators, such as Research Development, to predict how Silence Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Research Development | 78.1 M | 82 M |
Pair Trading with Silence Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silence Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Silence Stock
| 0.69 | GXEA | Galapagos NV | PairCorr |
| 0.67 | CMB | Cambium Bio | PairCorr |
| 0.66 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
| 0.64 | EQ | Equillium | PairCorr |
| 0.62 | DNTH | Dianthus Therapeutics | PairCorr |
The ability to find closely correlated positions to Silence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silence Therapeutics PLC to buy it.
The correlation of Silence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silence Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Silence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Silence Therapeutics Correlation against competitors. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Will Biotechnology sector continue expanding? Could Silence diversify its offerings? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Silence Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.35) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets | Return On Equity |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Silence Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.